Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 12:05 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 919 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Invasive Cancer Clear all

Conditions: Breast Cancer
Interventions: 3D-Conformal External Beam; Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2022
U.S. locations: 57
States / cities: Peoria, Arizona • Burbank, California • Aurora, Colorado + 44 more

Conditions: Invasive Breast Cancer Early Stages, Ductal Carcinoma In Situ, DCIS
Interventions: VENUS SHELL™ immobilization device; Device
Lead sponsor: HeroSupport SA; Industry
Eligibility: 40 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer
Interventions: Bevacizumab, Cyclophosphamide, Methotrexate, Capecitabine; Drug
Lead sponsor: Harold J. Burstein, MD, PhD; Other
Eligibility: 18 Years and older
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 5
States / cities: San Francisco, California • Indianapolis, Indiana • Boston, Massachusetts + 1 more

Conditions: Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma
Interventions: ASP546C; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 31
States / cities: Birmingham, Alabama • Los Angeles, California • Orange, California + 28 more

Conditions: Bladder Cancer
Interventions: Nivolumab, Gemcitabine, Cisplatin; Drug
Lead sponsor: Matthew Galsky; Other
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 7
States / cities: Duarte, California • Los Angeles, California • New York, New York + 4 more

Conditions: Bladder Cancer, Urethral Cancer
Interventions: cisplatin, ifosfamide, paclitaxel; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2007
U.S. locations: 1
States / cities: New York, New York

Conditions: Urinary Bladder Cancer
Interventions: Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200; Drug
Lead sponsor: Taris Biomedical LLC; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 5
States / cities: Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 2 more

Conditions: Prostate Cancer
Interventions: Radio-Frequency Ablation (RFA) ENCAGE™; Procedure
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, HER2/Neu Positive, Invasive Breast Carcinoma, Progesterone Receptor Negative, Progesterone Receptor Positive, Stage IA Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Triple-Negative Breast Carcinoma
Interventions: Cyclophosphamide, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel, Radiation Therapy, Therapeutic Conventional Surgery, Trastuzumab; Drug · Other · Radiation + 2 more
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older · Female only
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2025
U.S. locations: 4
States / cities: Bellevue, Nebraska • Grand Island, Nebraska • Omaha, Nebraska

Conditions: Breast Adenocarcinoma, Ductal Breast Carcinoma In Situ, Invasive Breast Carcinoma, Stage 0 Breast Cancer AJCC v6 and v7, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7
Interventions: Accelerated Partial Breast Irradiation, Proton Beam Radiation Therapy, Quality-of-Life Assessment; Radiation · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2032
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Bladder Cancer
Interventions: Pembrolizumab, Gemcitabine, Cisplatin, Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND]), Placebo; Drug · Procedure
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 907 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 24
States / cities: La Jolla, California • Santa Monica, California • Washington D.C., District of Columbia + 21 more

Conditions: Barrett Esophagus
Interventions: Biopsy, Biospecimen Collection, Endoscopic Procedure, Swallowable Sponge Cell Sampling Device; Procedure · Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 90 Years
Enrollment: 242 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2021
U.S. locations: 6
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Mankato, Minnesota + 3 more

Conditions: Breast Cancer
Interventions: Epirubicin, Cyclophosphamide, Docetaxel, Trastuzumab, Bevacizumab; Drug
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 18 Years and older · Female only
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 35
States / cities: Huntsville, Alabama • San Diego, California • Vallejo, California + 29 more

Conditions: Invasive Lobular Breast Carcinoma
Interventions: [18F]Fluoroestradiol (FES) PET/CT; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Invasive Ductal Breast Carcinoma, Invasive Ductal Carcinoma, Breast, DCIS, DCIS Grade 1, DCIS Grade 2, Breast Cancer
Interventions: Accelerated Partial Breast Irradiation; Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 45 Years and older · Female only
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 9
States / cities: Norwalk, Connecticut • Miami, Florida • Basking Ridge, New Jersey + 6 more

Conditions: Non-muscle Invasive Bladder Cancer
Interventions: CG0070; Biological
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Breast Cancer
Interventions: Fine Needle Aspiration (FNA), Ultrasound, Breast Surgery + Lymph Node Removal; Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Bilateral Breast Carcinoma, HER2/Neu Negative, Invasive Breast Carcinoma
Interventions: Best Practice, Ixabepilone; Other · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2026
U.S. locations: 3
States / cities: Oak Lawn, Illinois • Houston, Texas

Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma
Interventions: Biospecimen Collection, Extended Release Metformin Hydrochloride, Monitoring, Nutritional Assessment, Short-Term Fasting; Procedure · Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Vaginal Cancer
Interventions: Lymphoscintigraphy; Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Female only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Prostate Cancer
Interventions: Urine collection and blood draw; Procedure
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Breast Neoplasms
Interventions: Fine needle aspiration biopsy (FNAB), Sentinel Lymph Node Biopsy; Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Carcinoma in Situ, Non Muscle Invasive Bladder Cancer
Interventions: TMX-101; Drug
Lead sponsor: Telormedix SA; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 4
States / cities: Phoenix, Arizona • Denver, Colorado • Bala-Cynwyd, Pennsylvania + 1 more

Search by objective public record fields.

Radiation Therapy in Treating Women With Locally Recurrent Breast Cancer Previously Treated With Repeat Breast-Preserving Surgery

Personalized Prone Immobilization for Accelerated Partial Breast Radiotherapy

Bevacizumab With or Without Cyclophosphamide and Methotrexate: A Pilot Study in Women With Operable Breast Cancer

A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing

Combination Chemotherapy in Patients With Advanced Urinary Tract Cancer

Safety and Tolerability of GemRIS 225 mg in Subjects With Muscle-Invasive Bladder Cancer

Pilot Study on Focal Prostate Radio-Frequency Ablation

Fast Spectral Imaging Device for Tumor Margin Mapping

Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer

Radiation Therapy in Treating Patients With Stage 0-II Breast Cancer

Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)

A Minimally-Invasive Sponge on a String Device for Screening for Barrett's Esophagus

Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer

[18F]Fluoroestradiol-PET/CT Imaging of Invasive Lobular Carcinoma

Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer

Study of CG0070 After Transurethral Resection in Patients With IR NMIBC

Selective Image Guided Resection of Axillary Lymph Nodes

Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy

Metformin and Nightly Fasting in Women With Early Breast Cancer

Lymphoscintigraphy in Patients With Vaginal Cancer

Cancer DNA Detection in Blood and Urine

Testing of Different Methods for Determining Whether Breast Cancer Has Spread to the Lymph Nodes

Study With TMX-101 in Patients With Carcinoma In Situ (CIS) Bladder Cancer